The CJC-1295 plus ipamorelin combination is probably the most prescribed peptide stack in US wellness and anti-aging clinics. It pairs a growth hormone releasing hormone (GHRH) analog with a selective ghrelin receptor agonist to amplify endogenous growth hormone pulses. The rationale is that physiological pulsatile GH release is preferable to direct GH injection because it preserves feedback regulation and avoids supraphysiologic peaks.<\/p>\n
The actual evidence base is more limited than the marketing suggests. Both peptides have legitimate research histories. CJC-1295 was developed by ConjuChem in the early 2000s as a long-acting GHRH analog. Ipamorelin came out of pharmaceutical research at Novo Nordisk in the late 1990s as a selective ghrelin mimetic. Neither reached FDA approval. Both are now compounded by US pharmacies under section 503A, though the regulatory status has shifted under recent FDA review.<\/p>\n
This article walks through the actual mechanism, the published data, the practical dosing, and what these peptides can and can’t credibly deliver.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
GH release from the pituitary is regulated by two hypothalamic peptides.<\/strong> GHRH stimulates GH secretion. Somatostatin inhibits it. The interaction of these two creates pulsatile GH release, with major pulses overnight during slow-wave sleep.<\/p>\n Quick Answer: CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective ghrelin receptor agonist<\/p>\n A third regulator, ghrelin, also stimulates GH release through a different receptor (GHSR1a). Ghrelin synergizes with GHRH, producing larger GH pulses than either alone.<\/p>\n CJC-1295 is a GHRH analog with structural modifications that resist degradation. The original CJC-1295 had a drug affinity complex (DAC) that bound to serum albumin, giving it a multi-day half-life. The version most commonly used today, often called CJC-1295 without DAC or “Mod GRF 1-29,” lacks the DAC and has a half-life of about 30 minutes, allowing it to mimic physiological GHRH pulses.<\/p>\n Ipamorelin is a selective GHSR1a agonist. Unlike older ghrelin mimetics, it doesn’t significantly affect prolactin, cortisol, or ACTH. That selectivity is the source of its clean tolerability profile.<\/p>\n Combined, the two peptides hit the GH axis from both regulatory inputs, producing larger and more reliable GH pulses than either alone.<\/p>\n CJC-1295 with DAC has a long half-life, multiple days, which produces sustained elevation in GHRH signaling.<\/strong> This sounds appealing but produces a non-pulsatile pattern that loses some of the physiological advantages of native GH release.<\/p>\n CJC-1295 without DAC (also called mod GRF 1-29) has a short half-life and is dosed multiple times per day or, more commonly, paired with ipamorelin at bedtime to amplify the natural overnight GH pulse.<\/p>\n Most current protocols use CJC-1295 without DAC. The DAC version is less commonly prescribed in 2026, partly because of regulatory concerns and partly because the pulsatile rationale favors the shorter-acting version.<\/p>\n The clinical trial database is modest.<\/strong> CJC-1295 was studied in phase 1 and 2 trials by ConjuChem in the early 2000s. A 2006 study in 49 healthy adults reported sustained increases in IGF-1 levels for 6 to 8 days after a single dose of CJC-1295 with DAC, with a dose-response relationship across 30 to 250 mcg per kg.<\/p>\n Ipamorelin was studied as a separate program, with research papers showing selective GH release without prolactin or cortisol effects across multiple species and small human studies. The selectivity profile is well-characterized.<\/p>\n The combination CJC-1295 plus ipamorelin doesn’t have a large randomized human trial in healthy adults for functional outcomes like body composition or strength gains. Most reported outcomes come from observational data in wellness clinics, not from controlled trials.<\/p>\n In contrast, the GH literature itself is much larger. Recombinant GH in adults with GH deficiency improves body composition, exercise capacity, and quality of life. Whether peptide-induced endogenous GH elevation produces equivalent functional changes in adults without documented deficiency isn’t established.<\/p>\n Standard protocols vary by clinic but follow common patterns.<\/strong> CJC-1295 without DAC at 100 to 300 mcg combined with ipamorelin at 100 to 300 mcg, given by subcutaneous injection once or twice daily. The most common regimen is a single bedtime injection to amplify the natural overnight GH pulse, with some patients adding a morning dose.<\/p>\n Cycling is common, typically 3 to 6 months of daily injection followed by a 1 to 3 month washout. The rationale for cycling is to avoid receptor desensitization and to allow periodic assessment of whether the patient continues to benefit.<\/p>\n Monitoring usually includes baseline and periodic IGF-1, with adjustment of dose to keep IGF-1 in the upper-normal range for age. Some clinics also monitor body composition, sleep quality, and subjective response.<\/p>\n Reported benefits from CJC-1295 plus ipamorelin in wellness clinic settings include improved sleep depth, modest reduction in visceral adipose, mild improvement in lean body mass, and subjective improvements in recovery from exercise.<\/strong> Effect sizes are usually modest compared with what people imagine.<\/p>\n What the stack does not credibly deliver is the kind of dramatic body composition change associated with exogenous recombinant GH at supraphysiologic doses, which is illegal for non-medical use and carries significant side effects. The peptide stack works within the body’s normal feedback loops, which limits the magnitude of effect.<\/p>\n For meaningful body composition change in adults without GH deficiency, the most evidence-based interventions remain resistance training, adequate protein intake, sleep optimization, and if metabolically appropriate, GLP-1 therapy for weight loss with preservation of lean mass through training.<\/p>\n The CJC-1295 plus ipamorelin combination is generally well-tolerated in published research and in clinical practice.<\/strong> Reported side effects include injection site reactions, transient flushing, mild headache, and water retention. Some patients report increased hunger from ghrelin receptor activity, though ipamorelin’s selectivity means this effect is milder than with non-selective ghrelin mimetics.<\/p>\n Theoretical concerns include effects on insulin sensitivity (GH antagonizes insulin), elevated IGF-1 with potential effects on cancer risk in susceptible patients, and effects on prolactin or cortisol with non-selective ghrelin mimetics (which ipamorelin avoids).<\/p>\n Carpal tunnel syndrome, joint aches, and edema are reported in some patients on prolonged GH-secretagogue therapy, similar to known side effects of recombinant GH. These usually resolve with dose reduction or cessation.<\/p>\n Key Takeaway: Modest published clinical data on IGF-1 elevation; sparse data on functional outcomes<\/p>\n The IGF-1 elevation is the main concern.<\/strong> Higher IGF-1 levels have been associated with increased risk of certain cancers in epidemiologic data, including some breast, prostate, and colorectal cancers. Whether modest IGF-1 elevation in healthy adults using peptide stacks increases cancer risk to a clinically meaningful degree isn’t established.<\/p>\n In adults with active or recent cancer, GH-axis stimulation is generally avoided. For prevention contexts, the lack of long-term outcome data means the risk-benefit calculation is incomplete. Conservative practice keeps IGF-1 in the upper-normal range for age rather than pushing it above that.<\/p>\n Neither CJC-1295 nor ipamorelin is FDA-approved.<\/strong> For years they were available through 503A compounding pharmacies for individual patient prescriptions. The FDA’s 2023 review of compoundable peptides moved several including CJC-1295 and ipamorelin into more restricted categories, narrowing availability.<\/p>\n Some compounding pharmacies stopped offering them. Others continued through various pathways including clinical study, expanded access, and individual case-by-case review. Patients should expect availability to be variable across pharmacies and time.<\/p>\n International sourcing carries risks including unverified product quality, customs issues, and lack of medical oversight. Research-grade peptides from online vendors are not FDA-cleared or sterility-tested for human injection.<\/p>\n Recombinant human GH (somatotropin) is FDA-approved for adult GH deficiency, certain pediatric short stature indications, and HIV-associated wasting.<\/strong> For approved indications, GH replacement is well-supported and produces consistent body composition and quality of life improvements.<\/p>\n Off-label GH use for anti-aging or athletic performance is illegal under the Anabolic Steroid Control Act and FDCA, with significant criminal and civil enforcement. Despite that, off-label GH use exists, with significant side effect risks including hypertension, diabetes, joint problems, and possible cardiovascular and cancer effects.<\/p>\n The CJC-1295 plus ipamorelin stack is positioned as a more physiological alternative. The effect size is smaller, the side effect profile is cleaner, and the regulatory landscape is more permissive (though tightening). For most adults without diagnosed GH deficiency, the peptide stack is probably the safer choice if any GH-axis intervention is to be used.<\/p>\n The GLP-1 class is dramatically more effective for weight loss than GH-secretagogue stacks.<\/strong> STEP 1 (Wilding 2021 NEJM) showed 14.9% weight loss with semaglutide at 68 weeks. SURMOUNT-1 (Jastreboff 2022 NEJM) showed 20.9% with tirzepatide at 72 weeks. SELECT (Lincoff 2023 NEJM) showed 20% MACE reduction in patients with cardiovascular disease and overweight or obesity.<\/p>\n GH-secretagogue peptides produce single-digit percent body composition changes at best in healthy adults, with much weaker outcome data. For weight loss as a primary goal, the evidence-based path is GLP-1 therapy plus lifestyle change.<\/p>\n Some clinicians combine GLP-1 therapy with peptide GH secretagogues with the rationale of preserving lean mass during weight loss. The combination hasn’t been formally tested in trials. Adequate protein intake and resistance training are the better-validated levers for lean mass preservation during weight loss.<\/p>\n TrimRx is a telehealth platform offering compounded semaglutide and tirzepatide. The free assessment quiz determines if you qualify, and the personalized treatment plan structures therapy.<\/p>\n Bottom line: Neither peptide is FDA-approved; 503A compounding pharmacy access has narrowed since 2023<\/p>\n Modest effect at best. Reported reductions in visceral adipose are single-digit percent in observational data, much smaller than GLP-1 weight loss. For weight loss as a primary goal, GLP-1 medicines are dramatically more effective.<\/p>\n Reported effects on lean mass are modest. For meaningful muscle gain, resistance training with adequate protein is the foundation. Peptide stacks may add a small amount on top of that in adults with normal GH axis function.<\/p>\n Many patients report improved subjective sleep quality, particularly deeper slow-wave sleep, which makes physiological sense because GH release is concentrated in slow-wave sleep. Objective sleep architecture changes aren’t well-documented in trials.<\/p>\n Tesamorelin is a GHRH analog FDA-approved for HIV-associated lipodystrophy. It has more clinical data and an FDA pathway. It’s not approved for general anti-aging use. CJC-1295 plus ipamorelin is a compounded stack without FDA approval, used in wellness clinic settings.<\/p>\n Common protocols use 3 to 6 months on with 1 to 3 months off. The rationale is to avoid receptor desensitization and allow assessment of continued benefit. No formal trial defines optimal cycling.<\/p>\n Bedtime dosing amplifies the natural overnight GH pulse and is the most common single-dose timing. Twice-daily protocols add a morning dose. Mid-day dosing is less common because it interferes with normal pulsatile patterns less efficiently.<\/p>\n Short and medium-term safety data is reassuring with minimal side effects. Long-term outcome data, especially for cancer risk with sustained IGF-1 elevation, is not available. Conservative practice keeps IGF-1 in the upper-normal range for age and cycles therapy.<\/p>\n Most primary care physicians don’t prescribe peptide GH secretagogues. Wellness, anti-aging, and hormone optimization clinics are the typical prescribers, working with compounding pharmacies that prepare the products.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n The CJC-1295 plus ipamorelin combination is probably the most prescribed peptide stack in US wellness and anti-aging clinics.<\/p>\n","protected":false},"author":11,"featured_media":92661,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"CJC-1295 + Ipamorelin Stack: The Most Popular GH Protocol Explained","_yoast_wpseo_metadesc":"The CJC-1295 plus ipamorelin combination is probably the most prescribed peptide stack in US wellness and anti-aging clinics.","_yoast_wpseo_focuskw":"cjc1295 ipamorelin stack","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[40],"class_list":["post-89265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity","tag-peptides"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89265"}],"version-history":[{"count":2,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89265\/revisions"}],"predecessor-version":[{"id":93662,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89265\/revisions\/93662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92661"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What’s the Difference Between CJC-1295 DAC and Without DAC?<\/h2>\n
What Does the Published Evidence Show?<\/h2>\n
How Is the Stack Dosed?<\/h2>\n
What Can Patients Realistically Expect?<\/h2>\n
What Are the Side Effects?<\/h2>\n
What About Safety in Cancer Risk?<\/h2>\n
What’s the Regulatory Status?<\/h2>\n
How Does This Compare to Recombinant GH?<\/h2>\n
Where Does This Fit Into Metabolic Health and Weight Loss?<\/h2>\n
FAQ<\/h2>\n
Will CJC-1295 Plus Ipamorelin Help Me Lose Weight?<\/h3>\n
Can I Use the Stack for Muscle Building?<\/h3>\n
Does CJC-1295 Plus Ipamorelin Improve Sleep?<\/h3>\n
What’s the Difference Between This Stack and Tesamorelin?<\/h3>\n
How Long Should I Cycle Off?<\/h3>\n
Do I Need to Inject Before BED?<\/h3>\n
Is the Stack Safe Long-term?<\/h3>\n
Can I Get the Stack From My Regular Doctor?<\/h3>\n
Related Articles<\/h2>\n
\n